DeciBio acquires MDx and oncology databases, promotes Andrew Aijian

DeciBio Consulting, a strategy consulting and market intelligence firm focused on precision medicine, has acquired the molecular diagnostic (MDx) infectious disease and oncology databases of The Emmes Group, a biotech and pharmaceutical–focused management consultancy. DeciBio also announced the promotion of consultant Andrew Aijian to partner.

The database acquisition, effective January 1, 2020, enhances the solutions DeciBio offers to its clients. The Emmes MDx Database delivers customer-level metrics, insights, and data for molecular diagnostics tests and test panels, which manufacturers use to support sales, strategic marketing, and business development. The Emmes Oncology Database offers customer-level data on tissue-based testing in pathology, molecular oncology, and genetics labs in the US.

“We couldn’t be more excited to bring the Emmes Databases into the DeciBio portfolio of market intelligence offerings,” David Cavanaugh, DeciBio founding partner, said. “We’ve seen and experienced first-hand how useful these databases are in understanding and assessing molecular diagnostic testing actions and decisions at the user level.”

As part of the acquisition, DeciBio will take over the product development, sales, and marketing of the databases.

The Santa Monica, CA–based firm delivers growth planning, market assessment, product strategy, and corporate due diligence services to healthcare sector clients. DeciBio also offers market intelligence and insights to drive innovation in precision medicine. The firm works with clients ranging from incubator-stage startups to Fortune 500 healthcare corporations.

DeciBio also announced the promotion of Andrew Aijian to the level of partner – the first addition to the firm’s partnership since its founding in 2009. Aijian has been with the firm since 2013, and focuses on advising clients in oncology related-related research tools and diagnostics, strategies, and opportunities. He has led projects in infectious disease diagnostics, health IT, and genomics instruments and reagents, among other areas.

During his time at the consultancy, Aijian has also contributed to numerous market research reports, and advised on the spin-off of DeciBio Analytics – DeciBio’s market intelligence software technologies unit.

Aijian holds a PhD in biomedical engineering from UCLA, joining the firm as a PhD intern in 2013 and then as full-time employee in 2014.

“As one of our earliest employees, Andrew has been integral to the growth and development of DeciBio’s business and culture,” Stephane Budel, founding partner, said. “We describe ourselves as a meritocracy, and his path from PhD Intern to Partner is a testament to the fact that anyone can chart their own course here. I’m happy and excited to count him as a friend and business partner.”